<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16821">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151409</url>
  </required_header>
  <id_info>
    <org_study_id>NN8209-1940</org_study_id>
    <secondary_id>2008-000731-18</secondary_id>
    <nct_id>NCT02151409</nct_id>
  </id_info>
  <brief_title>Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>Netherlands: Dutch Health Care Inspectorate</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to develop a complement system
      targeted monoclonal antibody (mAb) to be used in treatment of subjects with chronic
      autoimmune diseases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Week 0-10</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Inflammation</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NNC 0151-0000-0000 i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC 0151-0000-0000 s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0151-0000-0000</intervention_name>
    <description>A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.</description>
    <arm_group_label>NNC 0151-0000-0000 i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC 0151-0000-0000</intervention_name>
    <description>A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels</description>
    <arm_group_label>NNC 0151-0000-0000 s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject)

          -  Body weight (BW) below or equal to 110.0 kg

          -  Body Mass Index (BMI) 20.0 - 27.0 kg/m^2, both inclusive

          -  Good state of health: evidenced by medical history, physical examination and results
             of laboratory examinations

        Exclusion Criteria:

          -  History of known or suspected cardiovascular diseases including: supine systolic
             blood pressure (BP) above or equal to 140 mmHg or below  90 mm Hg, diastolic BP above
             oe equal to 90 mm Hg or below 40 mm Hg, heart rate (HR) in supine position above 100
             beats/minute or below 45 beats/minute

          -  Hepatic insufficiency: Alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) above Upper Limit of Normal (ULN) (retesting is permitted within one week if
             first test is elevated but below 1.5 fold ULN)

          -  Renal insufficiency: Serum creatinine above ULN

          -  Positive for humane immunodeficiency virus (HIV) (by test)

          -  Positive for hepatitis B (HBV) or hepatitis C (HCV) (by test)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zuidlaren</city>
        <zip>9471 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
